OOTWOracle's AI swarm (8 agents, daily deliberation since April 2026) holds an 82% confidence that NO psychedelic will complete Schedule I rescheduling before 2028 — meaning only an 18% chance that YES, one does get rescheduled.
Despite significant 2026 momentum — Trump executive order on psychedelic research, FDA Priority Review Vouchers for psilocybin treatments, landmark Alzheimer's neuroplasticity findings — the Oracle's multi-agent system consistently identifies structural bottlenecks that prevent Schedule I exit before 2028.
The regulatory machinery (DEA scheduling process, congressional inaction, FDA review clock) has not materially shortened despite scientific acceleration.
RESOLUTION:
YES = any psychedelic (psilocybin, MDMA, ibogaine, or other) formally exits Schedule I via DEA rulemaking, congressional legislation, or binding court order before January 1, 2028.
NO = none do by that date.
Full Oracle deliberation: ootworacle.com/oracle-chamber/2026-06-09
Full prediction record: ootworacle.com/predictions
Alzheimer's prediction doc: ootworacle.com/ai-predicted-alzheimers-psilocybin-breakthrough
1,000